menu search

CTMX / CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023. Read More
Posted: Jan 6 2023, 15:03
Author Name: Zacks Investment Research
Views: 111724

CTMX News  

CytomX Therapeutics to Present at Upcoming September Investor Conferences

By GlobeNewsWire
September 5, 2023

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activ more_horizontal

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

By Zacks Investment Research
August 25, 2023

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for CytomX Therapeutics (CTMX) as it is technically in oversold territory now. In addition to this tec more_horizontal

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

CytomX Therapeutics, Inc. (CTMX) Q2 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2023 Results Conference Call August 8, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice Pres more_horizontal

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 8, 2023

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to more_horizontal

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

By GlobeNewsWire
June 1, 2023

CytomX Therapeutics to Present at the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activa more_horizontal

CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 9, 2023

CytomX Therapeutics, Inc. (CTMX) Q1 2023 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Chris Ogden - SVP, Finance & Acco more_horizontal

CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 9, 2023

CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to more_horizontal

CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 27, 2023

CytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call Transcript

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2022 Earnings Conference Call March 27, 2023 5:00 PM ET Company Participants Chris Ogden - SVP of Finance more_horizontal


Search within

Pages Search Results: